Healius Limited (ASX: HLS) - Share Price
Current share price for HLS : $0.375 0.025 (6.25%)+
Healius Limited (HLS), an ASX-listed company, is an Australian healthcare company that provides medical and related services such as private medical laboratory and pathology services across the country.
HLS General Information +
| ASX Code | HLS |
| Website | N/A |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 272 |
| HLS Share Price | $0.375 |
| Day High | $0.405 |
| Day Low | $0.370 |
| Last Close | $0.400 |
| HLS Share Price Movement | $0.03 ( 6.25% ) |
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Healius Limited (HLS) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 41.3¢ | 100% | 9 May 2025 | 23 May 2025 | - | - | - |
| HFResult | 6¢ | 100% | 7 Sep 2022 | 21 Sep 2022 | - | - | - |
| Result | 10¢ | 100% | 24 Mar 2022 | 5 Apr 2022 | - | - | - |
See all dividends from Healius Limited (HLS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Healius Limited (HLS) price-sensitive announcements
HLS - Healius transitions pathology arrangements with Ramsay
Healius Limited has announced a new national agreement framework with the wholly-owned sub
Healius Limited (HLS)
26 Jun 2026 | 5:09 PM
26 Jun 2026 | 5:09 PM
HLS - FY26 trading update and strategic review of assets
Healius Limited announced a trading update for FY26, projecting an underlying EBITDA betwe
Healius Limited (HLS)
13 May 2026 | 8:17 AM
13 May 2026 | 8:17 AM
HLS - Healius announces 1H 2026 results
Healius Limited announced its financial results for the first half of the fiscal year 2026
Healius Limited (HLS)
18 Feb 2026 | 8:16 AM
18 Feb 2026 | 8:16 AM
HLS - Half Year 2026 Results Presentation
Healius Limited's Half Year 2026 Results Presentation highlighted a group revenue growth o
Healius Limited (HLS)
18 Feb 2026 | 8:16 AM
18 Feb 2026 | 8:16 AM
Healius Limited (HLS) Recent ASX Announcements
HLS Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$2.00 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$2.00 | -59.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$35.80 | -$4.90 | -470.70% | 0.00 | 0.00 | 0.00% | 100.0% |
HLS Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Australian Clinical Labs Limited (ACL) | $450M | -0.0336 | 0.0000 | 0.0000 | 13.3076 | 0.0000 | 0.0000 | 5.19% | 0.00% | 0.00% |
| Healius Limited (HLS) | $290M | -4.7068 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Integral Diagnostics Limited (IDX) | $798M | -1.3095 | 0.5666 | 0.1667 | 27.9373 | 17.8333 | 15.2857 | 3.04% | 3.74% | 3.27% |
| Sonic Healthcare Limited (SHL) | $10,745M | 0.0625 | 0.1134 | 0.1484 | 20.3749 | 18.2997 | 15.9349 | 4.92% | 5.04% | 5.08% |
HLS Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Paul Anderson | Chief Executive Officer, Managing Director | 5 Mar 2024 |
| Ms Kathryn (Kate) Mary McKenzie | Non-Executive Chairman, Non-Executive Director | 25 Feb 2021 |
| Mr Christopher John Hall | Non-Executive Director | 30 Sep 2025 |
| Professor Bruce Gregory Robinson AC | Non-Executive Director | 2 Feb 2026 |
| Ms Sally Evans | Non-Executive Director | 21 Aug 2018 |
| Ms Katherine (Kathy) Ostin | Non-Executive Director | 1 Dec 2024 |
| Mr Charlie Taylor | Non-Executive Director | 20 Mar 2023 |
| Mr Steven Rubic | Non-Executive Director | 1 Dec 2025 |
Healius Limited (HLS) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Mar 2026 | RUBIC, Steven | Buy | Direct Shares | 130,000 | $0.595 | $77,350.000 |
| 12 Mar 2026 | OSTIN, Katherine (Kathy) | Buy | Indirect Shares | 8,547 | $0.585 | $4,999.995 |
| 9 Mar 2026 | OSTIN, Katherine (Kathy) | Buy | Indirect Shares | 16,264 | $0.615 | $9,999.107 |
See all changes in directors' interest & trades for Healius Limited (HLS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
HLS Management
| Name | Position |
|---|---|
| Puneet Nagi | Chief Operating Officer |
| Andrew Peter Thomson | Company Secretary |
| Kylie Brown | Company Secretary |
| Rodney Rudling | Group Executive, Clinical Integration |
| Anthea Muir | Group Executive, Customer & Commercial |
| Prasad Arav | Group Executive, Digital & Technology, and Strategy |
| Arjun Narang | Group Executive, Operations |
| Paula Bayliss | Group Executive, People & Culture |
| Kylie Brown | Group General Counsel, Company Secretary and Chief Risk Officer |
HLS Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Healius Limited (HLS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 68,203,075 (11.97%) | Tanarra Capital Australia Pty Ltd |
| 64,372,525 (8.87%) | Australian Retirement Trust Pty Ltd |
| 45,433,327 (7.97%) | Host-Plus Pty Limited |
| 53,280,727 (7.34%) | Spheria Asset Management Pty Ltd |
| 46,591,050 (6.42%) | Mitsubishi UFJ Financial Group, Inc |
| 46,578,502 (6.41%) | First Sentier Investors Holdings Pty Limited |
| 44,359,387 (6.11%) | Citicorp Global Markets Limited |
| 36,366,331 (5.01%) | Vanguard Group |
HLS Calendar of Events
| Date | Event |
|---|---|
| 17 February 2027 | Report (Interim) |
| 25 September 2026 | Report (Annual) |
| 20 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
